Tag : METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

  • HCC risk in MASLD extends beyond established cirrhosis, highlighting the need for more granular fibrosis-based risk stratification. A sequential approach, using the FIB-4 index for initial screening followed by liver stiffness measurement, may help identify patients at higher HCC risk who warrant further evaluation for surveillance and specialist referral.

    doctor name

    Professor Dr. Chan Wah Kheong

    Senior Consultant Gastroenterologist and Hepatologist, Universiti Malaya, Universiti Malaya Medical Centre and Universiti Malaya Specialist Centre, Kuala Lumpur, Malaysia

    doctor name

    Professor Yip, Cheuk-Fung Terry

    Associate Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

  • MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study